持续病毒学应答与失代偿期丙肝肝硬化肝相关事件的相关性
研究纳入914例接受直接抗病毒药物治疗的失代偿期HCV肝硬化患者,91.2%获得SVR。中位随访28个月,SVR与肝相关事件风险降低相关(aHR 0.692),但该获益仅限于基线MELD<15者,MELD≥15者无显著获益。
要点
- 失代偿期HCV肝硬化患者获得SVR与肝相关事件风险降低独立相关。
- SVR的获益仅在基线MELD<15患者中显著,MELD≥15者未观察到获益。
- SVR后MELD下降≥2分与肝相关事件风险降低无显著关联。
核心结论
- 在失代偿期HCV肝硬化且MELD<15的患者中,SVR与肝相关事件风险降低相关;MELD≥15者即使获得SVR也无明显临床获益。
研究设计与样本
- 纳入914例接受直接抗病毒药物治疗的失代偿期HCV肝硬化患者(CTP≥7和/或既往失代偿史),中位年龄54.7岁,45%有酒精使用障碍,87%为CTP-B级,中位MELD评分12.1。
主要发现
- 834例(91.2%)获得SVR,中位随访28个月;SVR组3年肝相关事件累积发生率为47.5%,非SVR组为58.6%(P<.001)。
- 多变量分析显示SVR与肝相关事件风险降低独立相关(aHR 0.692;P=.011)。
- 基线MELD<15者中,SVR组与非SVR组肝相关事件发生率分别为44.4%与57.6%(aHR 0.601;P=.004)。
- 基线MELD≥15者中,SVR组与非SVR组肝相关事件发生率分别为62.8%与58.9%(aHR 0.936;P=.801)。
- SVR患者中23.4%出现MELD下降≥2分,其肝相关事件发生率与未下降者无显著差异(52.1% vs 50.7%;P=.473)。
临床怎么用
- 对失代偿期HCV肝硬化患者,应结合基线MELD评分评估SVR的预期获益,MELD<15者可从SVR中获得肝相关事件风险降低。
- MELD≥15的失代偿期患者即使获得SVR,仍需密切监测肝相关事件,不能仅依赖SVR或MELD下降判断预后改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sustained virological response (SVR) improves prognosis in patients with chronic hepatitis C virus (HCV) with compensated cirrhosis, but whether a similar benefit can be obtained in decompensated patients is controversial. We studied the association between SVR and liver-related events (LREs) in patients with decompensated HCV cirrhosis. METHODS: We included patients with decompensated HCV cirrhosis (Child-Turcotte-Pugh [CTP] ≥7 and/or history of decompensation) treated with direct-acting antivirals. The association between SVR and LREs, and between SVR-related change in Model for End-stage Liver Disease (MELD) score and LREs were assessed. RESULTS: In total, 914 patients were included, with a median age of 54.7 years; 45% had alcohol use disorder, 87% CTP-B, and the median MELD score was 12.1. SVR was achieved in 834 patients (91.2%), with a median follow-up of 28 months. The 3-year cumulative incidence of LREs was 47.5% in patients with SVR compared with 58.6% in those without (P < .001). Findings were consistent in multivariable analysis (adjusted hazard ratio [aHR], 0.692; P = .011). SVR was associated with a reduced risk of LREs in patients with a pretreatment MELD <15 (44.4% vs 57.6%; aHR, 0.601; P = .004), but not among patients with MELD ≥15 (62.8% vs 58.9%; aHR, 0.936; P = .801). Among patients with SVR, a ≥2-point decrease in MELD was observed in 23.4% and was not associated with a reduced risk of LREs (52.1% vs 50.7%; P = .473). Findings were consistent in multivariable analysis (aHR, 0.730; P = .122), and in patients with a pretreatment MELD score ≥15. CONCLUSIONS: SVR was associated with a reduced risk of LREs in patients with decompensated HCV cirrhosis with a MELD score <15, whereas no clinical benefit was observed in those with higher MELD scores despite an SVR-associated MELD decrease.
引用
- van Velsen LM, Krassenburg LAP, Hirode G, et al. Association Between Sustained Virological Response and Adverse Liver-Related Events in Patients With Decompensated Hepatitis C Virus Cirrhosis. Clin Gastroenterol Hepatol. 2025. PMID: 40962195. doi:10.1016/j.cgh.2025.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。